Fosun Pharmaceutical announced that the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received approval from the State Drug Administration to conduct phase II/III adaptive seamless design clinical trials for the treatment of non-segmental vitiligo; the company plans to conduct related clinical research in China after conditions are met.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.